Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences

Susan L Karam; Jared Dendy; Shruti Polu; Lawrence Blonde

doi:10.2337/ds19-0029

Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences

Diabetes Spectr. 2020 Feb;33(1):8-15. doi: 10.2337/ds19-0029.

Authors

Susan L Karam¹, Jared Dendy¹, Shruti Polu¹, Lawrence Blonde¹

Affiliation

¹ Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA.

Abstract

Many people with diabetes do not achieve individualized treatment targets. Therapeutic inertia, the underuse of effective therapies in preventing serious clinical end points, is a frequent, important contributor to this failure. Clinicians, patients, health systems, payors, and producers of medications, devices, and other products for those with diabetes all play a role in the development of therapeutic inertia and can all help to reduce it.